Last reviewed · How we verify
TISA-818-Inj
At a glance
| Generic name | TISA-818-Inj |
|---|---|
| Sponsor | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Subjects After Subcutaneous Injection of TISA-818-Inj (PHASE1)
- Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TISA-818-Inj CI brief — competitive landscape report
- TISA-818-Inj updates RSS · CI watch RSS
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd. portfolio CI